<code id='5DBE167E83'></code><style id='5DBE167E83'></style>
    • <acronym id='5DBE167E83'></acronym>
      <center id='5DBE167E83'><center id='5DBE167E83'><tfoot id='5DBE167E83'></tfoot></center><abbr id='5DBE167E83'><dir id='5DBE167E83'><tfoot id='5DBE167E83'></tfoot><noframes id='5DBE167E83'>

    • <optgroup id='5DBE167E83'><strike id='5DBE167E83'><sup id='5DBE167E83'></sup></strike><code id='5DBE167E83'></code></optgroup>
        1. <b id='5DBE167E83'><label id='5DBE167E83'><select id='5DBE167E83'><dt id='5DBE167E83'><span id='5DBE167E83'></span></dt></select></label></b><u id='5DBE167E83'></u>
          <i id='5DBE167E83'><strike id='5DBE167E83'><tt id='5DBE167E83'><pre id='5DBE167E83'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:entertainment    Page View:452
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In